Back

Kir2.1 mutations differentially increase the risk of flecainide proarrhythmia in Andersen Tawil Syndrome

2024-12-11 cardiovascular medicine Title + abstract only
View on medRxiv
Show abstract

BackgroundFlecainide and other class-Ic antiarrhythmic drugs (AADs) are widely used in Andersen-Tawil syndrome type 1 (ATS1) patients. However, class-Ic drugs might be proarrhythmic in some cases. We investigated the molecular mechanisms of class-I AADs proarrhythmia and whether they might increase the risk of death in ATS1 patients with structurally normal hearts. Methods and ResultsOf 53 ATS1 patients reviewed from the literature, 54% responded partially to flecainide, with ventricular arrhyt...

Predicted journal destinations